KRAS and malignant colon neoplasm: The difference in DFS of stage III colon cancer patients that harbored a mutation in either APC and/or a mutation in one of the KRAS, BRAF, NRAS genes from the MAPK pathway compared to patients that were wild-type (WT) for these genes was even more pronounced than for APC mutation status alone (p = 0.002; HR =7 .5; Figure 4H), while such an association was not observed in stage II patients (Figure 4G).